Objective: Nasal-valve dilation reduces nasal
resistance and increases air flow. It is possible that this mechanism
prevents hypopharyngeal collapse and sleep apneas. We investigated the
effect of a plastic device (Nozovent; Prevancure AB; Västra
Frölunda, Sweden)—which dilates the nasal valve—on patients
with obstructive sleep apnea (OSA).
Prospective interventional study.
consecutive patients with OSA were included (22 men; mean ± SD age,
54.8 ± 11.3 years; respiratory disturbance index [RDI],
34.4 ± 18.5 events/h; body mass index, 31.6 ± 5.7
Intervention: The nasal dilator
was inserted during sleep into the nares and fitted to exert a dilating
force on the nasal valves by means of its elasticity.
Measurements: Polysomnographic studies were performed
before and after 1 month of treatment. A responder is defined as one
with a reduction in RDI to < 50% of the baseline value and RDI of≤
10 events/h during treatment.
patients dropped out. As a result, only 21 patients were analyzed. Four
patients responded, and 17 patients were nonresponders. In the whole
population, neither the mean values for respiration during sleep nor
sleep staging changed significantly with the device.
Conclusions: The investigated nasal dilator had no effect
on sleep-related breathing disorders in patients with moderate to
severe OSA. The reduction in nasal resistance does not prevent